EP3902531A4 - Pharmaceutical combinations comprising fingolimod and a spasmolytic - Google Patents

Pharmaceutical combinations comprising fingolimod and a spasmolytic Download PDF

Info

Publication number
EP3902531A4
EP3902531A4 EP19904739.0A EP19904739A EP3902531A4 EP 3902531 A4 EP3902531 A4 EP 3902531A4 EP 19904739 A EP19904739 A EP 19904739A EP 3902531 A4 EP3902531 A4 EP 3902531A4
Authority
EP
European Patent Office
Prior art keywords
fingolimod
spasmolytic
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19904739.0A
Other languages
German (de)
French (fr)
Other versions
EP3902531A2 (en
Inventor
Melda MISIRLI
Nur PEHLIVAN AKALIN
Muge ULUSOY BOZYEL
Seyhan TURKKAN
Yavuz Dedeoglu
Burce CIFCI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3902531A2 publication Critical patent/EP3902531A2/en
Publication of EP3902531A4 publication Critical patent/EP3902531A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19904739.0A 2018-12-28 2019-11-28 Pharmaceutical combinations comprising fingolimod and a spasmolytic Withdrawn EP3902531A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/20976A TR201820976A2 (en) 2018-12-28 2018-12-28 PHARMACEUTICAL COMBINATIONS WITH FINGOLIMOD AND A SPASMOLITHIC
PCT/TR2019/051008 WO2020139238A2 (en) 2018-12-28 2019-11-28 Pharmaceutical combinations comprising fingolimod and a spasmolytic

Publications (2)

Publication Number Publication Date
EP3902531A2 EP3902531A2 (en) 2021-11-03
EP3902531A4 true EP3902531A4 (en) 2022-06-01

Family

ID=71130184

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19904739.0A Withdrawn EP3902531A4 (en) 2018-12-28 2019-11-28 Pharmaceutical combinations comprising fingolimod and a spasmolytic

Country Status (3)

Country Link
EP (1) EP3902531A4 (en)
TR (1) TR201820976A2 (en)
WO (1) WO2020139238A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073510A1 (en) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions
US20160367540A1 (en) * 2007-04-26 2016-12-22 Sanochemia Pharmazeutika Ag Compositions of tolperisone
WO2018082814A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis
EP3398595A1 (en) * 2012-08-03 2018-11-07 Fwp Ip Aps Combination therapy for treatment of multiple sclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201720406A2 (en) * 2017-12-14 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi COMBINATIONS CONTAINING A SKELETAL MUSCLE LOAER AND A MULTIPLE SCLEROSIS THERAPY

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160367540A1 (en) * 2007-04-26 2016-12-22 Sanochemia Pharmazeutika Ag Compositions of tolperisone
EP3398595A1 (en) * 2012-08-03 2018-11-07 Fwp Ip Aps Combination therapy for treatment of multiple sclerosis
WO2016073510A1 (en) * 2014-11-04 2016-05-12 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions
WO2018082814A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SACCÀ FRANCESCO ET AL: "The use of medical-grade cannabis in patients non-responders to Nabiximols", JOURNAL OF NEUROLOGICAL SCIENCES, ELSEVIER SCIENTIFIC PUBLISHING CO, AMSTERDAM, NL, vol. 368, 26 July 2016 (2016-07-26), pages 349 - 351, XP029703114, ISSN: 0022-510X, DOI: 10.1016/J.JNS.2016.07.059 *
See also references of WO2020139238A2 *

Also Published As

Publication number Publication date
WO2020139238A3 (en) 2020-07-30
WO2020139238A2 (en) 2020-07-02
EP3902531A2 (en) 2021-11-03
TR201820976A2 (en) 2020-07-21

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP3802562A4 (en) New pharmaceutical use
EP3297624A4 (en) A pharmaceutical co-crystal and use thereof
EP3873443A4 (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
EP3688147B8 (en) A novel drug delivery system and methods providing thereof
EP3760616A4 (en) 4-methyldihydropyrimidinone compound and medicinal use thereof
EP3976014A4 (en) A combination comprising alogliptin and metformin
EP3749356A4 (en) A vaccine composition and uses thereof
EP3999056A4 (en) Pharmaceutical combination and use thereof
EP3851108A4 (en) Borate-based drug and use thereof
EP3749289A4 (en) A multiparticulate including pharmaceutical or probiotic active ingredients
EP3902531A4 (en) Pharmaceutical combinations comprising fingolimod and a spasmolytic
IL289481A (en) Pharmaceutical preparations comprising a benzonitrile derivative and their preparation
EP4069233A4 (en) Pharmaceutical combination and use thereof
PT3873438T (en) A chewable tablet and method of preparing the same
EP3733176A4 (en) Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof
EP4061369A4 (en) A pharmaceutical form comprising acidic substance
EP3592333A4 (en) A pharmaceutical composition comprising racecadotril and process for preparing the same
EP4031179A4 (en) Pharmaceutical combination and use thereof
ZA202103380B (en) Substituted 1,2,4-oxadiazole, its application and a pharmaceutical preparation comprising it
EP3810110A4 (en) A combination comprising fingolimod and amantadine
SG10201912063PA (en) A pharmaceutical formulation
EP3903781A4 (en) Pharmaceutical preparation
GB2564515B (en) Pharmaceutical composition and a method for manufacturing the same
EP3818532A4 (en) A medicine reminder system

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210727

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220429

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/24 20060101ALI20220422BHEP

Ipc: A61P 25/00 20060101ALI20220422BHEP

Ipc: A61K 9/22 20060101ALI20220422BHEP

Ipc: A61K 45/06 20060101ALI20220422BHEP

Ipc: A61K 31/4453 20060101ALI20220422BHEP

Ipc: A61K 31/137 20060101AFI20220422BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221129